What Is It?
Avanafil is a prescription PDE5 inhibitor approved by the FDA in 2012, designed for rapid onset.
Product Profile & Review
The newest FDA-approved PDE5 inhibitor, notable for a fast onset that can begin around 15 minutes.
Also known as: Stendra (brand), Spedra (EU brand)
Avanafil is a prescription PDE5 inhibitor approved by the FDA in 2012, designed for rapid onset.
A claimed ingredient is what a label or seller states. It is not treated as confirmed.
Established
Uncertain or unverified
Sexual stimulation releases nitric oxide (NO) in penile tissue. NO raises levels of cyclic GMP (cGMP), which relaxes the smooth muscle of the corpus cavernosum so arteries widen and blood flows in.
The enzyme PDE5 normally breaks cGMP down. PDE5 inhibitors block that enzyme, so cGMP persists and smooth-muscle relaxation is sustained. They do not create arousal—stimulation is still required.
Grades run from A (strong clinical evidence) to F (unsupported or contradicted). How we grade.
Common effects
Headache, flushing, nasal congestion and back pain.
FDA-approved for erectile dysfunction.
SynMale scores are editorial comparison tools and are not medical efficacy guarantees.
SynMale numerical ratings are editorial comparison tools informed by:
These numbers are not efficacy percentages, clinical success rates, or predictions of individual response.
Full methodology →Approved, effective, and fast-acting, with a shorter post-market history than older agents.
Avanafil is an FDA-approved tablet that can start working faster than other ED pills. It has less long-term real-world data. Standard PDE5 safety rules apply.